Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?

Aliment Pharmacol Ther. 2020 Sep;52(6):1076-1077. doi: 10.1111/apt.16025.

Authors

Desmond Chee^{1

2}, James R Goodhand^{1

2}, Tariq Ahmad^{1

2}

Affiliations

¹ Exeter IBD and Pharmacogenetics Research Group, Exeter, UK.
² Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

PMID: 33119171
DOI: 10.1111/apt.16025

No abstract available

Publication types

Editorial
Comment

MeSH terms

Drug-Related Side Effects and Adverse Reactions*
Humans
Inflammatory Bowel Diseases* / drug therapy
Inflammatory Bowel Diseases* / genetics
Pharmacogenetics
Pharmacogenomic Testing